{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:21:27Z","timestamp":1794853287070,"version":"4.9.1"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41581-025-01011-7","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:48:55Z","timestamp":1760028535000},"page":"12-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["RNA-based therapeutic opportunities for the treatment of kidney diseases"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-5076","authenticated-orcid":false,"given":"Jurri\u00ebn","family":"Prins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-9265","authenticated-orcid":false,"given":"Annabelle","family":"Biscans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1676-7738","authenticated-orcid":false,"given":"Anton Jan","family":"van Zonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall S.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-0181","authenticated-orcid":false,"given":"Eric P.","family":"van der Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"1011_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku, E., Lee, B. J., Wei, J. & Weir, M. R. Hypertension in CKD: core curriculum 2019. Am. J. Kidney Dis. 74, 120\u2013131 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"1011_CR2","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas, M. C. et al. Diabetic kidney disease. Nat. Rev. Dis. Prim. 1, 15018 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1011_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0004268","volume":"5","author":"DM Kelly","year":"2025","unstructured":"Kelly, D. M. et al. Global availability of medications and health technologies for kidney care: a multinational study from the ISN-GKHA. PLOS Glob. Public. Health 5, e0004268 (2025).","journal-title":"PLOS Glob. Public. Health"},{"key":"1011_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1011_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","volume":"5","author":"RS Finkel","year":"2021","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Lancet Child. Adolesc. Health 5, 491\u2013500 (2021).","journal-title":"Lancet Child. Adolesc. Health"},{"key":"1011_CR6","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1182\/blood.2024027008","volume":"145","author":"G Young","year":"2025","unstructured":"Young, G. et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood 145, 2966\u20132977 (2025).","journal-title":"Blood"},{"key":"1011_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","volume":"42","author":"V Jadhav","year":"2024","unstructured":"Jadhav, V., Vaishnaw, A., Fitzgerald, K. & Maier, M. A. RNA interference in the era of nucleic acid therapeutics. Nat. Biotechnol. 42, 394\u2013405 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR8","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli, M. & Manoharan, M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51, 2529\u20132573 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","volume":"120","author":"RS Wright","year":"2024","unstructured":"Wright, R. S. et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc. Res. 120, 1400\u20131410 (2024).","journal-title":"Cardiovasc. Res."},{"key":"1011_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa146.LB002","volume":"35","author":"S Garrelfs","year":"2020","unstructured":"Garrelfs, S. et al. J. LB002 Illuminate-A, a phase 3 study of lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1). Nephrol. Dial. Transplant. 35, gfaa146.LB002 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1011_CR11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2024.02.1439","volume":"9","author":"J Groothoff","year":"2024","unstructured":"Groothoff, J. et al. Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3. Kidney Int. Rep. 9, 1387\u20131396 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1011_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ekir.2024.12.014","volume":"10","author":"E Braekman","year":"2025","unstructured":"Braekman, E., Raes, A., De Bruyne, R., Verloo, P. & Prytula, A. Concomitant treatment with lumasiran and nedosiran in a child with primary hyperoxaluria type 1. Kidney Int. Rep. 10, 620\u2013621 (2025).","journal-title":"Kidney Int. Rep."},{"key":"1011_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary, R. S. Antisense oligonucleotide pharmacokinetics and metabolism. Expert. Opin. Drug. Metab. Toxicol. 5, 381\u2013391 (2009).","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"1011_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40119-024-00353-w","volume":"13","author":"H Thau","year":"2024","unstructured":"Thau, H., Neuber, S., Emmert, M. Y. & Nazari-Shafti, T. Z. Targeting lipoprotein(a): can RNA therapeutics provide the next step in the prevention of cardiovascular disease? Cardiol. Ther. 13, 39\u201367 (2024).","journal-title":"Cardiol. Ther."},{"key":"1011_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0076-6879(74)34090-6","volume":"34","author":"WE Pricer Jr.","year":"1974","unstructured":"Pricer, W. E. Jr., Hudgin, R. L., Ashwell, G., Stockert, R. J. & Morell, A. G. A membrane receptor protein for asialoglycoproteins. Methods Enzymol. 34, 688\u2013691 (1974).","journal-title":"Methods Enzymol."},{"key":"1011_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1126\/science.186.4161.365","volume":"186","author":"RJ Stockert","year":"1974","unstructured":"Stockert, R. J., Morell, A. G. & Scheinberg, I. H. Mammalian hepatic lectin. Science 186, 365\u2013366 (1974).","journal-title":"Science"},{"key":"1011_CR17","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1016\/S0021-9258(17)34586-6","volume":"253","author":"CP Stowell","year":"1978","unstructured":"Stowell, C. P. & Lee, Y. C. The binding of d-glucosyl-neoglycoproteins to the hepatic asialoglycoprotein receptor. J. Biol. Chem. 253, 6107\u20136110 (1978).","journal-title":"J. Biol. Chem."},{"key":"1011_CR18","doi-asserted-by":"publisher","first-page":"24024","DOI":"10.1074\/jbc.270.41.24024","volume":"270","author":"MH Chiu","year":"1995","unstructured":"Chiu, M. H., Thomas, V. H., Stubbs, H. J. & Rice, K. G. Tissue targeting of multivalent Lex-terminated N-linked oligosaccharides in mice. J. Biol. Chem. 270, 24024\u201324031 (1995).","journal-title":"J. Biol. Chem."},{"key":"1011_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1073\/pnas.79.2.350","volume":"79","author":"K Bridges","year":"1982","unstructured":"Bridges, K., Harford, J., Ashwell, G. & Klausner, R. D. Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc. Natl Acad. Sci. USA 79, 350\u2013354 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1011_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0021-9258(17)34164-9","volume":"254","author":"T Tanabe","year":"1979","unstructured":"Tanabe, T., Pricer, W. E. Jr. & Ashwell, G. Subcellular membrane topology and turnover of a rat hepatic binding protein specific for asialoglycoproteins. J. Biol. Chem. 254, 1038\u20131043 (1979).","journal-title":"J. Biol. Chem."},{"key":"1011_CR21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"1011_CR22","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958\u201316961 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"1011_CR23","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7255.1","volume":"5","author":"J Reiser","year":"2016","unstructured":"Reiser, J. & Altintas, M. M. Podocytes. F1000Res 5, F1000. https:\/\/doi.org\/10.12688\/f1000research.7255.1 (2016).","journal-title":"F1000Res"},{"key":"1011_CR24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1681\/ASN.2008070782","volume":"20","author":"JS Nielsen","year":"2009","unstructured":"Nielsen, J. S. & McNagny, K. M. The role of podocalyxin in health and disease. J. Am. Soc. Nephrol. 20, 1669\u20131676 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1011_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-024-00843-z","volume":"20","author":"K Meliambro","year":"2024","unstructured":"Meliambro, K., He, J. C. & Campbell, K. N. Podocyte-targeted therapies - progress and future directions. Nat. Rev. Nephrol. 20, 643\u2013658 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1011_CR26","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1016\/j.ymthe.2024.10.020","volume":"32","author":"V Kumar","year":"2024","unstructured":"Kumar, V. et al. Efficient and selective kidney targeting by chemically modified carbohydrate conjugates. Mol. Ther. 32, 4383\u20134400 (2024).","journal-title":"Mol. Ther."},{"key":"1011_CR27","doi-asserted-by":"publisher","unstructured":"Ding S. et al. Targeted delivery of siRNA to proximal tubule cells in kidney. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.20246phwmz9j (2024).","DOI":"10.1681\/ASN.20246phwmz9j"},{"key":"1011_CR28","doi-asserted-by":"publisher","first-page":"F1284","DOI":"10.1152\/ajprenal.00030.2020","volume":"318","author":"Q Ren","year":"2020","unstructured":"Ren, Q. et al. Distinct functions of megalin and cubilin receptors in recovery of normal and nephrotic levels of filtered albumin. Am. J. Physiol. Renal Physiol. 318, F1284\u2013F1294 (2020).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1011_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13959","volume":"238","author":"RT Alexander","year":"2023","unstructured":"Alexander, R. T. & Dimke, H. Effects of parathyroid hormone on renal tubular calcium and phosphate handling. Acta Physiol. 238, e13959 (2023).","journal-title":"Acta Physiol."},{"key":"1011_CR30","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1172\/JCI45161","volume":"121","author":"JV Bonventre","year":"2011","unstructured":"Bonventre, J. V. & Yang, L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 121, 4210\u20134221 (2011).","journal-title":"J. Clin. Invest."},{"key":"1011_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1046\/j.1523-1755.1999.00241.x","volume":"55","author":"R Largo","year":"1999","unstructured":"Largo, R. et al. Renal expression of parathyroid hormone-related protein (PTHrP) and PTH\/PTHrP receptor in a rat model of tubulointerstitial damage. Kidney Int. 55, 82\u201390 (1999).","journal-title":"Kidney Int."},{"key":"1011_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05075-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Zhu, L., Wang, X. & Jin, H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis. 13, 644 (2022).","journal-title":"Cell Death Dis."},{"key":"1011_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X. H. Antisense technology: an overview and prospectus. Nat. Rev. Drug. Discov. 20, 427\u2013453 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1011_CR34","unstructured":"FDA. Novel Drug Therapy Approvals for 2024 https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024 (2025)."},{"key":"1011_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker, U. et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 403, 249\u2013260 (2024).","journal-title":"Lancet"},{"key":"1011_CR36","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark, B. A. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N. Engl. J. Med. 390, 1770\u20131780 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238\u2013248 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR38","doi-asserted-by":"publisher","first-page":"12932","DOI":"10.1093\/nar\/gkx1073","volume":"45","author":"LJ Kielpinski","year":"2017","unstructured":"Kielpinski, L. J., Hagedorn, P. H., Lindow, M. & Vinther, J. RNase H sequence preferences influence antisense oligonucleotide efficiency. Nucleic Acids Res. 45, 12932\u201312944 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/hum.2015.070","volume":"26","author":"KE Lundin","year":"2015","unstructured":"Lundin, K. E., Gissberg, O. & Smith, C. I. Oligonucleotide therapies: the past and the present. Hum. Gene Ther. 26, 475\u2013485 (2015).","journal-title":"Hum. Gene Ther."},{"issue":"Pt 2","key":"1011_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1042\/bj3120599","volume":"312","author":"ST Crooke","year":"1995","unstructured":"Crooke, S. T. et al. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312(Pt 2), 599\u2013608 (1995).","journal-title":"Biochem. J."},{"key":"1011_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8969","volume":"6","author":"K Nishina","year":"2015","unstructured":"Nishina, K. et al. DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 6, 7969 (2015).","journal-title":"Nat. Commun."},{"key":"1011_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug. Deliv. Rev. 87, 46\u201351 (2015).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"1011_CR43","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1124\/dmd.119.087395","volume":"47","author":"N Post","year":"2019","unstructured":"Post, N. et al. Metabolism and disposition of volanesorsen, a 2\u2032-O-(2 methoxyethyl) antisense oligonucleotide, across species. Drug. Metab. Dispos. 47, 1164\u20131173 (2019).","journal-title":"Drug. Metab. Dispos."},{"key":"1011_CR44","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes, E. S. G. et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med. 390, 1781\u20131792 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.21","volume":"3","author":"J Zhou","year":"2014","unstructured":"Zhou, J. & Rossi, J. J. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol. Ther. Nucleic Acids 3, e169 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1011_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.59","volume":"2","author":"C Cheng","year":"2013","unstructured":"Cheng, C., Chen, Y. H., Lennox, K. A., Behlke, M. A. & Davidson, B. L. In vivo SELEX for identification of brain-penetrating aptamers. Mol. Ther. Nucleic Acids 2, e67 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1011_CR47","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas, E. S. et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805\u20132816 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR48","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani, A. M. et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402, 1449\u20131458 (2023).","journal-title":"Lancet"},{"key":"1011_CR49","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans, N. M. et al. Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 364, 1513\u20131522 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo, F. et al. Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46\u201355 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1011_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259\u2013293 (2010).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1011_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","volume":"38","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases. BioDrugs 38, 177\u2013203 (2024).","journal-title":"BioDrugs"},{"key":"1011_CR53","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh, N. N., Howell, M. D., Androphy, E. J. & Singh, R. N. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 24, 520\u2013526 (2017).","journal-title":"Gene Ther."},{"key":"1011_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09523-0","volume":"10","author":"P Denichenko","year":"2019","unstructured":"Denichenko, P. et al. Specific inhibition of splicing factor activity by decoy RNA oligonucleotides. Nat. Commun. 10, 1590 (2019).","journal-title":"Nat. Commun."},{"key":"1011_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","volume":"76","author":"J Ule","year":"2019","unstructured":"Ule, J. & Blencowe, B. J. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell 76, 329\u2013345 (2019).","journal-title":"Mol. Cell"},{"key":"1011_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41581-021-00497-1","volume":"18","author":"L Seufert","year":"2022","unstructured":"Seufert, L., Benzing, T., Ignarski, M. & Muller, R. U. RNA-binding proteins and their role in kidney disease. Nat. Rev. Nephrol. 18, 153\u2013170 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1011_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/epigenomes4010002","volume":"4","author":"RG de Bruin","year":"2020","unstructured":"de Bruin, R. G. et al. Targeting the RNA-binding protein QKI in myeloid cells ameliorates macrophage-induced renal interstitial fibrosis. Epigenomes 4, 2\u00a0(2020).","journal-title":"Epigenomes"},{"key":"1011_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna, J. A. & Charpentier, E. Genome editing. the new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).","journal-title":"Science"},{"key":"1011_CR59","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul, H. et al. Exagamglogene autotemcel for severe sickle cell disease. N. Engl. J. Med. 390, 1649\u20131662 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR60","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst, H. J. et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N. Engl. J. Med. 390, 432\u2013441 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR61","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019\u20131027 (2017).","journal-title":"Science"},{"key":"1011_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41587-019-0013-6","volume":"37","author":"T Merkle","year":"2019","unstructured":"Merkle, T. et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat. Biotechnol. 37, 133\u2013138 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR63","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","volume":"37","author":"L Qu","year":"2019","unstructured":"Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat. Biotechnol. 37, 1059\u20131069 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR64","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1021\/jacs.0c13319","volume":"143","author":"EE Doherty","year":"2021","unstructured":"Doherty, E. E. et al. Rational design of RNA editing guide strands: cytidine analogs at the orphan position. J. Am. Chem. Soc. 143, 6865\u20136876 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"1011_CR65","doi-asserted-by":"publisher","first-page":"10068","DOI":"10.1093\/nar\/gkae681","volume":"52","author":"G Lu","year":"2024","unstructured":"Lu, G. et al. Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing. Nucleic Acids Res. 52, 10068\u201310084 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41587-024-02313-0","volume":"43","author":"P Reautschnig","year":"2025","unstructured":"Reautschnig, P. et al. Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA. Nat. Biotechnol. 43, 545\u2013557 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR67","unstructured":"ProQR. ProQR Announces Second Quarter 2025 Operating and Financial Results, https:\/\/www.proqr.com\/press-releases\/proqr-announces-second-quarter-2025-operating-and-financial-results (2025)."},{"key":"1011_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0034-1397344","volume":"35","author":"AM Mohr","year":"2015","unstructured":"Mohr, A. M. & Mott, J. L. Overview of microRNA biology. Semin. Liver Dis. 35, 3\u201311 (2015).","journal-title":"Semin. Liver Dis."},{"key":"1011_CR69","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-022-00608-6","volume":"18","author":"N Mahtal","year":"2022","unstructured":"Mahtal, N., Lenoir, O., Tinel, C., Anglicheau, D. & Tharaux, P. L. MicroRNAs in kidney injury and disease. Nat. Rev. Nephrol. 18, 643\u2013662 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1011_CR70","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Krutzfeldt","year":"2005","unstructured":"Krutzfeldt, J. et al. Silencing of microRNAs in vivo with \u2018antagomirs\u2019. Nature 438, 685\u2013689 (2005).","journal-title":"Nature"},{"key":"1011_CR71","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/1389557515666150324123208","volume":"15","author":"B Simonson","year":"2015","unstructured":"Simonson, B. & Das, S. MicroRNA therapeutics: the next magic bullet? Mini Rev. Med. Chem. 15, 467\u2013474 (2015).","journal-title":"Mini Rev. Med. Chem."},{"key":"1011_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11918-y","volume":"10","author":"EC Lee","year":"2019","unstructured":"Lee, E. C. et al. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat. Commun. 10, 4148 (2019).","journal-title":"Nat. Commun."},{"key":"1011_CR73","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806\u2013811 (1998).","journal-title":"Nature"},{"key":"1011_CR74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature02872","volume":"431","author":"CC Mello","year":"2004","unstructured":"Mello, C. C. & Conte, D. Jr. Revealing the world of RNA interference. Nature 431, 338\u2013342 (2004).","journal-title":"Nature"},{"key":"1011_CR75","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/nar\/gky1239","volume":"47","author":"A Biscans","year":"2019","unstructured":"Biscans, A. et al. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. Nucleic Acids Res. 47, 1082\u20131096 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR76","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","volume":"29","author":"A Biscans","year":"2021","unstructured":"Biscans, A. et al. Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles. Mol. Ther. 29, 1382\u20131394 (2021).","journal-title":"Mol. Ther."},{"key":"1011_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr, O. B. et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J. Rare Dis. 10, 109 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"1011_CR78","doi-asserted-by":"publisher","first-page":"17337","DOI":"10.1073\/pnas.0607015103","volume":"103","author":"LC Li","year":"2006","unstructured":"Li, L. C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl Acad. Sci. USA 103, 17337\u201317342 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1011_CR79","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ymthe.2017.07.018","volume":"25","author":"J Voutila","year":"2017","unstructured":"Voutila, J. et al. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol. Ther. 25, 2705\u20132714 (2017).","journal-title":"Mol. Ther."},{"key":"1011_CR80","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/nar\/gkw076","volume":"44","author":"X Meng","year":"2016","unstructured":"Meng, X. et al. Small activating RNA binds to the genomic target site in a seed-region-dependent manner. Nucleic Acids Res. 44, 2274\u20132282 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR81","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4155\/tde-2018-0061","volume":"10","author":"A Kwok","year":"2019","unstructured":"Kwok, A., Raulf, N. & Habib, N. Developing small activating RNA as a therapeutic: current challenges and promises. Ther. Deliv. 10, 151\u2013164 (2019).","journal-title":"Ther. Deliv."},{"key":"1011_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102041","volume":"6","author":"R Plummer","year":"2025","unstructured":"Plummer, R. et al. TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. Cell Rep. Med. 6, 102041\u00a0(2025).","journal-title":"Cell Rep. Med."},{"key":"1011_CR83","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1021\/ja00718a039","volume":"92","author":"F Eckstein","year":"1970","unstructured":"Eckstein, F. Nucleoside phosphorothioates. J. Am. Chem. Soc. 92, 4718\u20134723 (1970).","journal-title":"J. Am. Chem. Soc."},{"key":"1011_CR84","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1128\/AAC.37.9.1945","volume":"37","author":"RF Azad","year":"1993","unstructured":"Azad, R. F., Driver, V. B., Tanaka, K., Crooke, R. M. & Anderson, K. P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37, 1945\u20131954 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1011_CR85","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0040-4039(01)90461-7","volume":"22","author":"SL Beaucage","year":"1981","unstructured":"Beaucage, S. L. & Caruthers, M. H. Deoxynucleoside phosphoramidites \u2014 a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22, 1859\u20131862 (1981).","journal-title":"Tetrahedron Lett."},{"key":"1011_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207956119","volume":"119","author":"BT Le","year":"2022","unstructured":"Le, B. T. et al. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing. Proc. Natl Acad. Sci. USA 119, e2207956119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1011_CR87","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bsheal.2022.03.003","volume":"4","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Biosafety assessment of delivery systems for clinical nucleic acid therapeutics. Biosaf. Health 4, 105\u2013117 (2022).","journal-title":"Biosaf. Health"},{"key":"1011_CR88","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto, N. et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 35, 845\u2013851 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR89","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1093\/nar\/gkac018","volume":"50","author":"P Kandasamy","year":"2022","unstructured":"Kandasamy, P. et al. Control of backbone chemistry and chirality boost oligonucleotide splice switching activity. Nucleic Acids Res. 50, 5443\u20135466 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR90","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/9304","volume":"6","author":"M Teplova","year":"1999","unstructured":"Teplova, M. et al. Crystal structure and improved antisense properties of 2\u2032-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6, 535\u2013539 (1999).","journal-title":"Nat. Struct. Biol."},{"key":"1011_CR91","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","volume":"97","author":"C Wahlestedt","year":"2000","unstructured":"Wahlestedt, C. et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA 97, 5633\u20135638 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1011_CR92","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1021\/jo902560f","volume":"75","author":"PP Seth","year":"2010","unstructured":"Seth, P. P. et al. Synthesis and biophysical evaluation of 2\u2032,4\u2032-constrained 2\u2032O-methoxyethyl and 2\u2032,4\u2032-constrained 2\u2032O-ethyl nucleic acid analogues. J. Org. Chem. 75, 1569\u20131581 (2010).","journal-title":"J. Org. Chem."},{"key":"1011_CR93","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1093\/nar\/gkh516","volume":"32","author":"BH Yoo","year":"2004","unstructured":"Yoo, B. H., Bochkareva, E., Bochkarev, A., Mou, T. C. & Gray, D. M. 2\u2032-O-Methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 32, 2008\u20132016 (2004).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR94","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1093\/nar\/gkv162","volume":"43","author":"TP Prakash","year":"2015","unstructured":"Prakash, T. P. et al. Identification of metabolically stable 5\u2032-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Res. 43, 2993\u20133011 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02989-4","volume":"9","author":"MM Janas","year":"2018","unstructured":"Janas, M. M. et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat. Commun. 9, 723 (2018).","journal-title":"Nat. Commun."},{"key":"1011_CR96","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0022-3565(24)35315-7","volume":"292","author":"S Henry","year":"2000","unstructured":"Henry, S. et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292, 468\u2013479 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1011_CR97","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/nar\/gky1260","volume":"47","author":"HJ Gaus","year":"2019","unstructured":"Gaus, H. J. et al. Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Res. 47, 1110\u20131122 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR98","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","volume":"17","author":"M Shadid","year":"2021","unstructured":"Shadid, M., Badawi, M. & Abulrob, A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin. Drug. Metab. Toxicol. 17, 1281\u20131292 (2021).","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"1011_CR99","unstructured":"Ernstmeyer, K., Christmann, E. Nursing Pharmacology. (Chippewa Valley Technical College, 2023)."},{"key":"1011_CR100","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/nar\/gky037","volume":"46","author":"MR Hassler","year":"2018","unstructured":"Hassler, M. R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185\u20132196 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR101","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/nat.2015.0598","volume":"26","author":"JA Engelhardt","year":"2016","unstructured":"Engelhardt, J. A. Comparative renal toxicopathology of antisense oligonucleotides. Nucleic Acid. Ther. 26, 199\u2013209 (2016).","journal-title":"Nucleic Acid. Ther."},{"key":"1011_CR102","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","volume":"18","author":"A Amantana","year":"2007","unstructured":"Amantana, A. et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18, 1325\u20131331 (2007).","journal-title":"Bioconjug. Chem."},{"key":"1011_CR103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.tox.2012.06.005","volume":"301","author":"SP Henry","year":"2012","unstructured":"Henry, S. P. et al. Renal uptake and tolerability of a 2\u2032-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology 301, 13\u201320 (2012).","journal-title":"Toxicology"},{"key":"1011_CR104","unstructured":"Levin, A. A., Yu, R. Z. & Geary, R. S. Antisense Drug Technology: Principles, Strategies and Applications. (CRC Press, 2007)."},{"key":"1011_CR105","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0192623318789399","volume":"46","author":"KS Frazier","year":"2018","unstructured":"Frazier, K. S. & Obert, L. A. Drug-induced glomerulonephritis: the spectre of biotherapeutic and antisense oligonucleotide immune activation in the kidney. Toxicol. Pathol. 46, 904\u2013917 (2018).","journal-title":"Toxicol. Pathol."},{"key":"1011_CR106","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/mt.2016.136","volume":"24","author":"ST Crooke","year":"2016","unstructured":"Crooke, S. T. et al. Integrated safety assessment of 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol. Ther. 24, 1771\u20131782 (2016).","journal-title":"Mol. Ther."},{"key":"1011_CR107","unstructured":"Frazier, K. S., Seely, J. C. Toxicologic Pathology (CRC Press, 2018)."},{"key":"1011_CR108","unstructured":"Khan, K. N. M ., Alden, C. L. Haschek, W., Rousseaux, C., Wallig, M. (eds). Handbook of Toxicologic Pathology. (Academic Press, 2024)"},{"key":"1011_CR109","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.omtn.2019.08.025","volume":"18","author":"MJ Janssen","year":"2019","unstructured":"Janssen, M. J. et al. Therapy with 2\u2032-O-Me phosphorothioate antisense oligonucleotides causes reversible proteinuria by inhibiting renal protein reabsorption. Mol. Ther. Nucleic Acids 18, 298\u2013307 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1011_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ooc.2022.100022","volume":"4","author":"P Caetano-Pinto","year":"2022","unstructured":"Caetano-Pinto, P. et al. Epidermal growth factor receptor mediates the basolateral uptake of phosphorothioate-modified antisense oligonucleotides in the kidney. Organs Chip 4, 100022 (2022).","journal-title":"Organs Chip"},{"key":"1011_CR111","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/nat.2017.0693","volume":"28","author":"ST Crooke","year":"2018","unstructured":"Crooke, S. T. et al. The effects of 2\u2032-O-methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid. Ther. 28, 10\u201322 (2018).","journal-title":"Nucleic Acid. Ther."},{"key":"1011_CR112","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1177\/0192623313505781","volume":"42","author":"KS Frazier","year":"2014","unstructured":"Frazier, K. S. et al. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol. Pathol. 42, 923\u2013935 (2014).","journal-title":"Toxicol. Pathol."},{"key":"1011_CR113","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri, K. et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J. Clin. Med. 9, 2004\u00a0(2020).","journal-title":"J. Clin. Med."},{"key":"1011_CR114","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/0192623320964391","volume":"48","author":"A Sandelius","year":"2020","unstructured":"Sandelius, A. et al. Urinary kidney biomarker panel detects preclinical antisense oligonucleotide-induced tubular toxicity. Toxicol. Pathol. 48, 981\u2013993 (2020).","journal-title":"Toxicol. Pathol."},{"key":"1011_CR115","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden, H. & Munro, J. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug. Discov. 18, 495\u2013496 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1011_CR116","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison, R. K. Phase II and phase III failures: 2013\u20132015. Nat. Rev. Drug. Discov. 15, 817\u2013818 (2016).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1011_CR117","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1681\/ASN.2008111204","volume":"20","author":"BA Molitoris","year":"2009","unstructured":"Molitoris, B. A. et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 20, 1754\u20131764 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1011_CR118","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3727\/096368910X516619","volume":"19","author":"R Imamura","year":"2010","unstructured":"Imamura, R. et al. Intravital two-photon microscopy assessment of renal protection efficacy of siRNA for p53 in experimental rat kidney transplantation models. Cell Transpl. 19, 1659\u20131670 (2010).","journal-title":"Cell Transpl."},{"key":"1011_CR119","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","volume":"144","author":"M Thielmann","year":"2021","unstructured":"Thielmann, M. et al. Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation 144, 1133\u20131144 (2021).","journal-title":"Circulation"},{"key":"1011_CR120","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03510897 (2021)."},{"key":"1011_CR121","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41581-023-00694-0","volume":"19","author":"AB Sanz","year":"2023","unstructured":"Sanz, A. B., Sanchez-Nino, M. D., Ramos, A. M. & Ortiz, A. Regulated cell death pathways in kidney disease. Nat. Rev. Nephrol. 19, 281\u2013299 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1011_CR122","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2215\/CJN.0000000000000458","volume":"19","author":"DP Gale","year":"2024","unstructured":"Gale, D. P. et al. A randomized controlled clinical trial testing effects of lademirsen on kidney function decline in adults with Alport syndrome. Clin. J. Am. Soc. Nephrol. 19, 995\u20131004 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1011_CR123","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02855268 (2025)."},{"key":"1011_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.matbio.2016.08.005","volume":"57-58","author":"D Cosgrove","year":"2017","unstructured":"Cosgrove, D. & Liu, S. Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome. Matrix Biol. 57-58, 45\u201354 (2017).","journal-title":"Matrix Biol."},{"key":"1011_CR125","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.112.197426","volume":"343","author":"TA Zanardi","year":"2012","unstructured":"Zanardi, T. A. et al. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J. Pharmacol. Exp. Ther. 343, 489\u2013496 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1011_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.292","volume":"5","author":"L van Meer","year":"2017","unstructured":"van Meer, L. et al. Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects. Pharmacol. Res. Perspect. 5, e00292 (2017).","journal-title":"Pharmacol. Res. Perspect."},{"key":"1011_CR127","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05065463 (2022)."},{"key":"1011_CR128","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/bcp.12738","volume":"80","author":"EP van Poelgeest","year":"2015","unstructured":"van Poelgeest, E. P. et al. Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br. J. Clin. Pharmacol. 80, 1350\u20131361 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1011_CR129","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.kint.2023.07.007","volume":"104","author":"T Sen","year":"2023","unstructured":"Sen, T. et al. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney Int. 104, 828\u2013839 (2023).","journal-title":"Kidney Int."},{"key":"1011_CR130","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.omtn.2016.11.006","volume":"6","author":"A Moisan","year":"2017","unstructured":"Moisan, A. et al. Inhibition of EGF uptake by nephrotoxic antisense drugs in vitro and implications for preclinical safety profiling. Mol. Ther. Nucleic Acids 6, 89\u2013105 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1011_CR131","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1128\/JVI.74.5.2420-2425.2000","volume":"74","author":"N Chirmule","year":"2000","unstructured":"Chirmule, N. et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74, 2420\u20132425 (2000).","journal-title":"J. Virol."},{"key":"1011_CR132","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.gt.3302768","volume":"13","author":"X Wang","year":"2006","unstructured":"Wang, X., Skelley, L., Cade, R. & Sun, Z. AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage. Gene Ther. 13, 1097\u20131103 (2006).","journal-title":"Gene Ther."},{"key":"1011_CR133","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1681\/ASN.2005111148","volume":"17","author":"Y Zhang","year":"2006","unstructured":"Zhang, Y. et al. Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. J. Am. Soc. Nephrol. 17, 1090\u20131101 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1011_CR134","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3390\/cells12182253","volume":"12","author":"P Mangla","year":"2023","unstructured":"Mangla, P., Vicentini, Q. & Biscans, A. Therapeutic oligonucleotides: an outlook on chemical strategies to improve endosomal trafficking. Cells 12, 2253 (2023).","journal-title":"Cells"},{"key":"1011_CR135","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy, S. F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 35, 222\u2013229 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR136","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00467-021-05352-w","volume":"38","author":"T Bondue","year":"2023","unstructured":"Bondue, T., van den Heuvel, L., Levtchenko, E. & Brock, R. The potential of RNA-based therapy for kidney diseases. Pediatr. Nephrol. 38, 327\u2013344 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"1011_CR137","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467\u20131475 (2017).","journal-title":"Mol. Ther."},{"key":"1011_CR138","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1011_CR139","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jconrel.2020.01.024","volume":"320","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Co-delivery of p38alpha MAPK and p65 siRNA by novel liposomal glomerulus-targeting nano carriers for effective immunoglobulin a nephropathy treatment. J. Control. Rel. 320, 457\u2013468 (2020).","journal-title":"J. Control. Rel."},{"key":"1011_CR140","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2013.12.029","volume":"176","author":"PS Kowalski","year":"2014","unstructured":"Kowalski, P. S. et al. Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo. J. Control. Rel. 176, 64\u201375 (2014).","journal-title":"J. Control. Rel."},{"key":"1011_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202313791","volume":"36","author":"A Vaidya","year":"2024","unstructured":"Vaidya, A. et al. Expanding RNAi to kidneys, lungs, and spleen via selective organ targeting (SORT) siRNA lipid nanoparticles. Adv. Mater. 36, e2313791 (2024).","journal-title":"Adv. Mater."},{"key":"1011_CR142","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 37, 107\u2013124 (2018).","journal-title":"Cancer Metastasis Rev."},{"key":"1011_CR143","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1681\/ASN.2009030295","volume":"21","author":"H Shimizu","year":"2010","unstructured":"Shimizu, H. et al. siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol. 21, 622\u2013633 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1011_CR144","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acs.molpharmaceut.0c00094","volume":"18","author":"N Raval","year":"2021","unstructured":"Raval, N., Jogi, H., Gondaliya, P., Kalia, K. & Tekade, R. K. Cyclo-RGD truncated polymeric nanoconstruct with dendrimeric templates for targeted HDAC4 gene silencing in a diabetic nephropathy mouse model. Mol. Pharm. 18, 641\u2013666 (2021).","journal-title":"Mol. Pharm."},{"key":"1011_CR145","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1124\/jpet.121.000667","volume":"378","author":"D Xie","year":"2021","unstructured":"Xie, D. et al. Kidney-targeted delivery of prolyl hydroxylase domain protein 2 small interfering RNA with nanoparticles alleviated renal ischemia\/reperfusion injury. J. Pharmacol. Exp. Ther. 378, 235\u2013243 (2021).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1011_CR146","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.7150\/thno.7866","volume":"4","author":"S Gao","year":"2014","unstructured":"Gao, S. et al. Megalin-mediated specific uptake of chitosan\/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing. Theranostics 4, 1039\u20131051 (2014).","journal-title":"Theranostics"},{"key":"1011_CR147","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.3390\/polym16172547","volume":"16","author":"MG Alameh","year":"2024","unstructured":"Alameh, M. G. et al. Chitosan siRNA nanoparticles produce significant non-toxic functional gene silencing in kidney cortices. Polymers 16, 2547 (2024).","journal-title":"Polymers"},{"key":"1011_CR148","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1021\/acscentsci.0c00763","volume":"6","author":"HBD Thai","year":"2020","unstructured":"Thai, H. B. D. et al. Kidney-targeted cytosolic delivery of siRNA using a small-sized mirror DNA tetrahedron for enhanced potency. ACS Cent. Sci. 6, 2250\u20132258 (2020).","journal-title":"ACS Cent. Sci."},{"key":"1011_CR149","doi-asserted-by":"publisher","first-page":"331ra339","DOI":"10.1126\/scitranslmed.aac9647","volume":"8","author":"S Alidori","year":"2016","unstructured":"Alidori, S. et al. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci. Transl. Med. 8, 331ra339 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1011_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0963-9","volume":"18","author":"KM McAndrews","year":"2019","unstructured":"McAndrews, K. M. & Kalluri, R. Mechanisms associated with biogenesis of exosomes in cancer. Mol. Cancer 18, 52 (2019).","journal-title":"Mol. Cancer"},{"key":"1011_CR151","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1681\/ASN.2020111561","volume":"32","author":"TT Tang","year":"2021","unstructured":"Tang, T. T. et al. Kim-1 targeted extracellular vesicles: a new therapeutic platform for RNAi to treat AKI. J. Am. Soc. Nephrol. 32, 2467\u20132483 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1011_CR152","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1093\/nar\/gkz354","volume":"47","author":"TP Prakash","year":"2019","unstructured":"Prakash, T. P. et al. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle. Nucleic Acids Res. 47, 6029\u20136044 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR153","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/nar\/gky1232","volume":"47","author":"MF Osborn","year":"2019","unstructured":"Osborn, M. F. et al. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways. Nucleic Acids Res. 47, 1070\u20131081 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR154","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/d41573-021-00213-5","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard, A. Antibody-oligonucleotide conjugates enter the clinic. Nat. Rev. Drug. Discov. 21, 6\u20138 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1011_CR155","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","volume":"51","author":"B Malecova","year":"2023","unstructured":"Malecova, B. et al. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs). Nucleic Acids Res. 51, 5901\u20135910 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1011_CR156","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1021\/nn700400h","volume":"2","author":"KL Hultman","year":"2008","unstructured":"Hultman, K. L. et al. Magnetic resonance imaging of major histocompatibility class II expression in the renal medulla using immunotargeted superparamagnetic iron oxide nanoparticles. ACS Nano 2, 477\u2013484 (2008).","journal-title":"ACS Nano"},{"key":"1011_CR157","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1002\/art.24026","volume":"58","author":"Y Scindia","year":"2008","unstructured":"Scindia, Y., Deshmukh, U., Thimmalapura, P. R. & Bagavant, H. Anti-\u03b18 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 58, 3884\u20133891 (2008).","journal-title":"Arthritis Rheum."},{"key":"1011_CR158","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3109\/1061186X.2012.693500","volume":"20","author":"T Shirai","year":"2012","unstructured":"Shirai, T., Kohara, H. & Tabata, Y. Inflammation imaging by silica nanoparticles with antibodies orientedly immobilized. J. Drug Target. 20, 535\u2013543 (2012).","journal-title":"J. Drug Target."},{"key":"1011_CR159","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7150\/thno.14915","volume":"6","author":"A Rubio-Navarro","year":"2016","unstructured":"Rubio-Navarro, A. et al. CD163-macrophages are involved in rhabdomyolysis-induced kidney injury and may be detected by MRI with targeted gold-coated iron oxide nanoparticles. Theranostics 6, 896\u2013914 (2016).","journal-title":"Theranostics"},{"key":"1011_CR160","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF02480453","volume":"2","author":"DJ Salant","year":"1998","unstructured":"Salant, D. J. Immune complex glomerulonephritis. Front. Nephrol. Clin. Exp. Nephrol. 2, 271\u2013275 (1998).","journal-title":"Front. Nephrol. Clin. Exp. Nephrol."},{"key":"1011_CR161","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1039\/C6SC02403C","volume":"8","author":"DA Richards","year":"2017","unstructured":"Richards, D. A., Maruani, A. & Chudasama, V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem. Sci. 8, 63\u201377 (2017).","journal-title":"Chem. Sci."},{"key":"1011_CR162","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtn.2017.06.018","volume":"8","author":"G Ranches","year":"2017","unstructured":"Ranches, G. et al. In vitro selection of cell-internalizing DNA aptamers in a model system of inflammatory kidney disease. Mol. Ther. Nucleic Acids 8, 198\u2013210 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1011_CR163","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nbt1223","volume":"24","author":"JO McNamara","year":"2006","unstructured":"McNamara, J. O. et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005\u20131015 (2006).","journal-title":"Nat. Biotechnol."},{"key":"1011_CR164","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/380364a0","volume":"380","author":"R Pasqualini","year":"1996","unstructured":"Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364\u2013366 (1996).","journal-title":"Nature"},{"key":"1011_CR165","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1046\/j.1523-1755.2002.00120.x","volume":"61","author":"A Audige","year":"2002","unstructured":"Audige, A., Frick, C., Frey, F. J., Mazzucchelli, L. & Odermatt, A. Selection of peptide ligands binding to the basolateral cell surface of proximal convoluted tubules. Kidney Int. 61, 342\u2013348 (2002).","journal-title":"Kidney Int."},{"key":"1011_CR166","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1166\/jnn.2012.6372","volume":"12","author":"YK Kim","year":"2012","unstructured":"Kim, Y. K. et al. Kidney-specific peptide-conjugated poly(ester amine) for the treatment of kidney fibrosis. J. Nanosci. Nanotechnol. 12, 5149\u20135154 (2012).","journal-title":"J. Nanosci. Nanotechnol."},{"key":"1011_CR167","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1021\/acs.bioconjchem.6b00057","volume":"27","author":"A Wischnjow","year":"2016","unstructured":"Wischnjow, A. et al. Renal targeting: peptide-based drug delivery to proximal tubule cells. Bioconjug. Chem. 27, 1050\u20131057 (2016).","journal-title":"Bioconjug. Chem."},{"key":"1011_CR168","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3892\/ijmm.2017.2902","volume":"39","author":"L Wu","year":"2017","unstructured":"Wu, L. et al. Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes. Int. J. Mol. Med. 39, 851\u2013860 (2017).","journal-title":"Int. J. Mol. Med."},{"key":"1011_CR169","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1002\/smll.201200733","volume":"8","author":"K Pollinger","year":"2012","unstructured":"Pollinger, K. et al. Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles. Small 8, 3368\u20133375 (2012).","journal-title":"Small"},{"key":"1011_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2024.110251","volume":"36","author":"M Yuan","year":"2025","unstructured":"Yuan, M. et al. Kidney targeted delivery of siRNA mediated by peptide-siRNA conjugate for the treatment of acute kidney injury. Chin. Chem. Lett. 36, 110251 (2025).","journal-title":"Chin. Chem. Lett."},{"key":"1011_CR171","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1021\/bc300020f","volume":"23","author":"Q Geng","year":"2012","unstructured":"Geng, Q., Sun, X., Gong, T. & Zhang, Z. R. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery. Bioconjug. Chem. 23, 1200\u20131210 (2012).","journal-title":"Bioconjug. Chem."},{"key":"1011_CR172","doi-asserted-by":"publisher","first-page":"F54","DOI":"10.1152\/ajprenal.00143.2016","volume":"312","author":"GL Bidwell","year":"2017","unstructured":"Bidwell, G. L. et al. A kidney-selective biopolymer for targeted drug delivery. Am. J. Physiol. Renal Physiol. 312, F54\u2013F64 (2017).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1011_CR173","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.bbrc.2014.01.107","volume":"444","author":"T Asai","year":"2014","unstructured":"Asai, T. et al. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. Biochem. Biophys. Res. Commun. 444, 599\u2013604 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1011_CR174","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3565(24)38034-6","volume":"288","author":"K Suzuki","year":"1999","unstructured":"Suzuki, K. et al. Specific renal delivery of sugar-modified low-molecular-weight peptides. J. Pharmacol. Exp. Ther. 288, 888\u2013897 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1011_CR175","first-page":"682","volume":"5","author":"KM Sand","year":"2014","unstructured":"Sand, K. M. et al. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol. 5, 682 (2014).","journal-title":"Front. Immunol."},{"key":"1011_CR176","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt, R. J. & Julian, B. A. IgA nephropathy. N. Engl. J. Med. 368, 2402\u20132414 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR177","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/j.ekir.2024.02.303","volume":"9","author":"J Barratt","year":"2024","unstructured":"Barratt, J. et al. Wcn24-912 IMAGINATION: a global phase 3 trial of Ro7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy. Kidney Int. Rep. 9, S147\u00a0(2024).","journal-title":"Kidney Int. Rep."},{"key":"1011_CR178","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","volume":"19","author":"J Barratt","year":"2024","unstructured":"Barratt, J. et al. Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 19, 452\u2013462 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1011_CR179","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic, V. et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N. Engl. J. Med. 392, 531\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0440","volume":"83","author":"AM De Bhailis","year":"2022","unstructured":"De Bhailis, A. M. & Kalra, P. A. Hypertension and the kidneys. Br. J. Hosp. Med. 83, 1\u201311 (2022).","journal-title":"Br. J. Hosp. Med."},{"key":"1011_CR181","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai, A. S. et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N. Engl. J. Med. 389, 228\u2013238 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR182","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","volume":"6","author":"ES Morgan","year":"2021","unstructured":"Morgan, E. S. et al. Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and phase 2 studies. JACC Basic Transl. Sci. 6, 485\u2013496 (2021).","journal-title":"JACC Basic Transl. Sci."},{"key":"1011_CR183","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/ndt\/gfv459","volume":"32,","author":"J Menne","year":"2017","unstructured":"Menne, J. et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol. Dial. Transpl. 32, 307\u2013315 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1011_CR184","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.ajpath.2017.07.020","volume":"187","author":"MGS Boels","year":"2017","unstructured":"Boels, M. G. S. et al. Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function in diabetic nephropathy. Am. J. Pathol. 187, 2430\u20132440 (2017).","journal-title":"Am. J. Pathol."},{"key":"1011_CR185","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41581-022-00538-3","volume":"18","author":"P Daneshpajouhnejad","year":"2022","unstructured":"Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307\u2013320 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1011_CR186","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126124","volume":"4","author":"M Aghajan","year":"2019","unstructured":"Aghajan, M. et al. Antisense oligonucleotide treatment ameliorates IFN-\u03b3-induced proteinuria in APOL-1-transgenic mice. JCI Insight 4, e126124\u00a0(2019).","journal-title":"JCI Insight"},{"key":"1011_CR187","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.ymthe.2022.04.007","volume":"30","author":"YW Yang","year":"2022","unstructured":"Yang, Y. W. et al. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice. Mol. Ther. 30, 2491\u20132504 (2022).","journal-title":"Mol. Ther."},{"key":"1011_CR188","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14728222.2023.2218616","volume":"27","author":"L Devlin","year":"2023","unstructured":"Devlin, L., Dhondurao Sudhindar, P. & Sayer, J. A. Renal ciliopathies: promising drug targets and prospects for clinical trials. Expert Opin. Ther. Targets 27, 325\u2013346 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1011_CR189","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1093\/hmg\/ddu208","volume":"23","author":"K Ravichandran","year":"2014","unstructured":"Ravichandran, K. et al. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum. Mol. Genet. 23, 4919\u20134931 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1011_CR190","doi-asserted-by":"publisher","first-page":"F349","DOI":"10.1152\/ajprenal.00478.2014","volume":"308","author":"K Ravichandran","year":"2015","unstructured":"Ravichandran, K., Ozkok, A., Wang, Q., Mullick, A. E. & Edelstein, C. L. Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2. Am. J. Physiol. Renal Physiol. 308, F349\u2013F357 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1011_CR191","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1096\/fj.15-279299","volume":"30","author":"T Saigusa","year":"2016","unstructured":"Saigusa, T. et al. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J. 30, 370\u2013379 (2016).","journal-title":"FASEB J."},{"key":"1011_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47243-z","volume":"9","author":"E Molinari","year":"2019","unstructured":"Molinari, E. et al. Targeted exon skipping rescues ciliary protein composition defects in Joubert syndrome patient fibroblasts. Sci. Rep. 9, 10828 (2019).","journal-title":"Sci. Rep."},{"key":"1011_CR193","doi-asserted-by":"publisher","first-page":"12489","DOI":"10.1073\/pnas.1809432115","volume":"115","author":"SA Ramsbottom","year":"2018","unstructured":"Ramsbottom, S. A. et al. Targeted exon skipping of a CEP290 mutation rescues Joubert syndrome phenotypes in vitro and in a murine model. Proc. Natl Acad. Sci. USA 115, 12489\u201312494 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1011_CR194","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","volume":"28","author":"SR Russell","year":"2022","unstructured":"Russell, S. R. et al. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial. Nat. Med. 28, 1014\u20131021 (2022).","journal-title":"Nat. Med."},{"key":"1011_CR195","unstructured":"ProQR. Phase 2\/3 Illuminate Trial results of sepofarsen in CEP290-mediated LCA10. https:\/\/www.proqr.com\/press-releases\/proqr-announces-top-line-results-from-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10 (11 February 2022)."},{"key":"1011_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04536688 (2021)."},{"key":"1011_CR197","unstructured":"Biospace. Regulus Therapeutics announces top-line data from the first cohort of phase 1b clinical trial of RGLS4326 for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD). https:\/\/www.biospace.com\/regulus-therapeutics-announces-top-line-data-from-the-first-cohort-of-phase-1b-clinical-trial-of-rgls4326-for-the-treatment-of-patients-with-autosomal-dominant-polycystic-kidney-disease-adpkd (3 May 2021)."},{"key":"1011_CR198","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.3390\/cells10113097","volume":"10","author":"MY Momin","year":"2021","unstructured":"Momin, M. Y., Gaddam, R. R., Kravitz, M., Gupta, A. & Vikram, A. The challenges and opportunities in the development of MicroRNA therapeutics: a multidisciplinary viewpoint. Cells 10, 3097 (2021).","journal-title":"Cells"},{"key":"1011_CR199","unstructured":"Novartis. Novartis completes acquisition of Regulus Therapeutics. https:\/\/www.novartis.com\/news\/media-releases\/novartis-completes-acquisition-regulus-therapeutics (25 June 2025)."},{"key":"1011_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122329","volume":"302","author":"R Pala","year":"2023","unstructured":"Pala, R., Barui, A. K., Mohieldin, A. M., Zhou, J. & Nauli, S. M. Folate conjugated nanomedicines for selective inhibition of mTOR signaling in polycystic kidneys at clinically relevant doses. Biomaterials 302, 122329 (2023).","journal-title":"Biomaterials"},{"key":"1011_CR201","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.15971020","volume":"17","author":"A Agrawal","year":"2022","unstructured":"Agrawal, A., Ison, M. G. & Danziger-Isakov, L. Long-term infectious complications of kidney transplantation. Clin. J. Am. Soc. Nephrol. 17, 286\u2013295 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1011_CR202","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR203","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR204","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote, V. et al. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1011_CR205","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1681\/ASN.2017050477","volume":"29","author":"V Nickeleit","year":"2018","unstructured":"Nickeleit, V. et al. The Banff working group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J. Am. Soc. Nephrol. 29, 680\u2013693 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1011_CR206","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1089\/nat.2025.0010","volume":"35","author":"J Prins","year":"2025","unstructured":"Prins, J. et al. Design and in vitro evaluation of a novel antisense oligonucleotide for treatment of BK virus infection. Nucleic Acid Ther. 35, 182\u2013197 (2025).","journal-title":"Nucleic Acid Ther."},{"key":"1011_CR207","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nrd.2016.67","volume":"15","author":"MD Breyer","year":"2016","unstructured":"Breyer, M. D. & Susztak, K. The next generation of therapeutics for chronic kidney disease. Nat. Rev. Drug. Discov. 15, 568\u2013588 (2016).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1011_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110801","volume":"110","author":"C Li","year":"2023","unstructured":"Li, C., Han, S., Zhu, J. & Cheng, F. MiR-132-3p activation aggravates renal ischemia-reperfusion injury by targeting Sirt1\/PGC1alpha axis. Cell Signal. 110, 110801 (2023).","journal-title":"Cell Signal."},{"key":"1011_CR209","first-page":"7794","volume":"13","author":"D Zhang","year":"2021","unstructured":"Zhang, D., Lu, H., Hou, W., Bai, Y. & Wu, X. Effect of miR-132-3p on sepsis-induced acute kidney injury in mice via regulating HAVCR1\/KIM-1. Am. J. Transl. Res. 13, 7794\u20137803 (2021).","journal-title":"Am. J. Transl. Res."},{"key":"1011_CR210","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.kint.2021.04.001","volume":"100","author":"AS Arykbaeva","year":"2021","unstructured":"Arykbaeva, A. S. et al. Metabolic needs of the kidney graft undergoing normothermic machine perfusion. Kidney Int. 100, 301\u2013310 (2021).","journal-title":"Kidney Int."},{"key":"1011_CR211","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.15689","volume":"20","author":"IMA Bruggenwirth","year":"2020","unstructured":"Bruggenwirth, I. M. A. & Martins, P. N. RNA interference therapeutics in organ transplantation: the dawn of a new era. Am. J. Transpl. 20, 931\u2013941 (2020).","journal-title":"Am. J. Transpl."},{"key":"1011_CR212","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/ajt.16929","volume":"22","author":"ER Thompson","year":"2022","unstructured":"Thompson, E. R. et al. MicroRNA antagonist therapy during normothermic machine perfusion of donor kidneys. Am. J. Transpl. 22, 1088\u20131100 (2022).","journal-title":"Am. J. Transpl."},{"key":"1011_CR213","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47106-w","volume":"15","author":"MJA de Haan","year":"2024","unstructured":"de Haan, M. J. A. et al. A cell-free nutrient-supplemented perfusate allows four-day ex vivo metabolic preservation of human kidneys. Nat. Commun. 15, 3818 (2024).","journal-title":"Nat. Commun."},{"key":"1011_CR214","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","volume":"24","author":"JS Mattick","year":"2023","unstructured":"Mattick, J. S. et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell Biol. 24, 430\u2013447 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1011_CR215","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2400718","volume":"391","author":"VS Ganesh","year":"2024","unstructured":"Ganesh, V. S. et al. Neurodevelopmental disorder caused by deletion of CHASERR, a lncRNA gene. N. Engl. J. Med. 391, 1511\u20131518 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR216","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1191426","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu, H., Wang, X., Gao, H., Yang, C. & Xie, C. Physiological and pathological characteristics of vascular endothelial injury in diabetes and the regulatory mechanism of autophagy. Front. Endocrinol. 14, 1191426 (2023).","journal-title":"Front. Endocrinol."},{"key":"1011_CR217","volume":"5","author":"A Aartsma-Rus","year":"2024","unstructured":"Aartsma-Rus, A., Collin, R. W. J., Elgersma, Y., Lauffer, M. C. & van Roon-Mom, W. Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics. Ther. Adv. Rare Dis. 5, 26330040241273465 (2024).","journal-title":"Ther. Adv. Rare Dis."},{"key":"1011_CR218","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR219","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013243","volume":"13","author":"SM Hammond","year":"2021","unstructured":"Hammond, S. M. et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol. Med. 13, e13243\u00a0(2021).","journal-title":"EMBO Mol. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01011-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:02:04Z","timestamp":1782334924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01011-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":219,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01011-7","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"17 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.P. is employee at Vico Therapeutics and declares no other competing interests. A.B. is employee at AstraZeneca and declares no other competing interests. A.J.v.Z. serves on the scientific advisory boards of Hybridize Therapeutics and the Dutch Kidney Foundation and declares no other competing interests. E.P.v.d.V is the founder, a shareholder and employee of Hybridize Therapeutics. K.S.F. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}